argenx SE (NASDAQ:ARGX) Shares Acquired by Syon Capital LLC

Syon Capital LLC lifted its holdings in argenx SE (NASDAQ:ARGX) by 4.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 897 shares of the company’s stock after buying an additional 37 shares during the period. Syon Capital LLC’s holdings in argenx were worth $552,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GeoWealth Management LLC increased its stake in shares of argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC increased its position in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd purchased a new position in argenx during the fourth quarter worth about $38,000. Finally, Jones Financial Companies Lllp boosted its holdings in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several analyst reports. William Blair reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Guggenheim upped their price target on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Citigroup boosted their price objective on shares of argenx from $681.00 to $796.00 and gave the company a “buy” rating in a report on Thursday, April 17th. Finally, JMP Securities increased their target price on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $699.28.

argenx Stock Performance

ARGX stock opened at $600.51 on Friday. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The company’s 50 day moving average price is $598.76 and its 200 day moving average price is $607.23. The firm has a market capitalization of $36.67 billion, a price-to-earnings ratio of -682.40 and a beta of 0.60.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Equities analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.